Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
Study Details
Study Description
Brief Summary
This is a single-arm, open-lable, multicenter phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PM1003 in the treatment of advanced solid tumors.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
PM1003 is a Bispecific Antibody Targeting PD-L1 and 4-1BB.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: PM1003 PM1003 0.02mg/kg-10mg/kg |
Biological: PM1003 Injection
Subjects will receive PM1003 by intravenous administration.
|
Outcome Measures
Primary Outcome Measures
- Dose Limited Toxicity(DLT) [up to 21 days]
Occurrence of DLT after receiving PM1003 injection
- Assess the incidence and severity of treatment-related adverse events [Up to 30 days after last treatment]
The incidence and severity of treatment-emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) graded according to NCI-CTCAE v5.0
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Voluntary participation in clinical study; fully understand the study and sign informed consent voluntarily; willing to follow and able to complete all test procedures;
-
Male or female aged 18 to 75 years;
-
Subjects with malignant tumor confirmed by histology or cytology;
-
Adequate organ function;
-
ECOG score was 0-1.
-
Pre-menopausal female subjects with negative blood pregnancy results within 7 days prior to the study treatment, and agree to abstain from sex or use medically approved effective contraceptive measures for 6 months from the date of signing the informed consent form to the end of the last medication;
-
Male subjects are agree to abstain from sex or use medically approved effective contraceptive methods for 6 months from the date of signing the informed consent form to the end of the last medication, and do not donate sperm during this period.
Exclusion Criteria:
-
History of severe allergic to macromolecular protein drugs, severe allergy to drugs or known allergy to any component of the drug in this study;
-
Treatment with any 4-1BB monoclonal antibody or 4-1BB-containing dual antibody immune co-stimulatory molecule agonist;
-
Current active infection requiring intravenous anti-infective therapy;
-
Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;
-
Known history of alcohol abuse, psychotropic drug abuse or drug abuse;
-
History of neurological or psychiatric disorders, such as epilepsy, dementia, schizophrenia, etc.;
-
Anticipated need for any other form of antineoplastic drug treatment during the trial;
-
Women who are pregnant or breastfeeding;
-
Other conditions lead to inappropriate to participate in this study as judged by the investigator.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Cancer Hospital Affiliated to Shandong First Medical University | Jinan | Shandong | China | |
2 | Shanghai Orient Hospital | Shanghai | China |
Sponsors and Collaborators
- Biotheus Inc.
Investigators
- Principal Investigator: Ye Guo, Shanghai Orient Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PM1003-AB001M-ST-R